Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
OCTREOTIDE TREATMENT IN PATIENTS WITH NECROTIZING PANCREATITIS AND PULMONARY FAILURE
Autore:
FIEDLER F; JAUERNIG G; KEIM V; RICHTER A; BENDER HJ;
Indirizzi:
UNIV HEIDELBERG,FAK KLIN MED MANNHEIM,INST ANASTHESIOL & INTENS MED,THEODOR KUTZER UFER 1-3 D-68167 MANNHEIM GERMANY UNIV LEIPZIG,MED KLIN & POLIKLIN 2 D-7010 LEIPZIG GERMANY UNIV HEIDELBERG,FAK KLIN MED MANNHEIM,KLINIKUM MANNHEIM,CHIRURG KLIN D-6800 MANNHEIM GERMANY
Titolo Testata:
Intensive care medicine
fascicolo: 9, volume: 22, anno: 1996,
pagine: 909 - 915
SICI:
0342-4642(1996)22:9<909:OTIPWN>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
SMS 201-995; MULTICENTER TRIAL; CLINICAL-TRIAL; APACHE-II; SOMATOSTATIN; PHARMACOKINETICS; SYSTEM;
Keywords:
ACUTE PANCREATITIS; NECROTIZING PANCREATITIS; OCTREOTIDE; TREATMENT; SYSTEMIC COMPLICATIONS; SIRS; ARDS; CIRCULATORY SHOCK;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
37
Recensione:
Indirizzi per estratti:
Citazione:
F. Fiedler et al., "OCTREOTIDE TREATMENT IN PATIENTS WITH NECROTIZING PANCREATITIS AND PULMONARY FAILURE", Intensive care medicine, 22(9), 1996, pp. 909-915

Abstract

Objective. To determine the efficiency of intravenous infusion of octreotide in the treatment of patients with severe pancreatitis and pulmonary failure. Design. Prospective case-control study. Setting: Intensive care unit of a university hospital. Patients. Treatment group: 39 patients with necrotizing pancreatitis were selected for the study. Inall, pulmonary failure developed under conservative treatment and surgical intervention had been necessary because of local (abscess, necrosis) or systemic (systemic inflammatory response syndrome) complications. The outcome was prospectively followed up until death or dischargefrom the hospital. Control group: 54 case-control matched patients with acute necrotizing pancreatitis and pulmonary failure, who had not been treated with octreotide. Intervention: Each patient in the treatment group received 100 mu g intravenous octreotide three times daily for 10 days, in addition to the standard intensive care therapy. Results: The groups (octreotide group, control group) were highly comparable with regard to age (mean age: 54, 51 years), sex, severity of illness (Acute Physiology and Chronic Health Evaluation II score: 27, 27), etiology of pancreatitis, and pretreatment at the time of admission to the intensive care unit. There was no difference in the development of renal, hepatic, gastrointestinal, hemostatic. neurologic, or local complications. But the frequency of the adult respiratory distress syndrome (18 vs 40%; (p < 0.05) and circulatory shock (51 vs 87%: p < 0.05 was significantly lower in the treatment group. Furthermore, mortality was 26% (10 of 39 patients) in the octreotide group and 61% (33 of 53 patients) in the control group (p < 0.01). Conclusion: The results of our case-control study showed a beneficial effect of octreotide in patients with severs necrotizing pancreatitis and pulmonary failure. Basedon these data, a prospective, double-blind, placebo-controlled study should be performed to evaluate these results.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/08/20 alle ore 09:20:55